Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab

about

Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor alpha therapy.

P2860

Q47561508-44BE1426-F603-443C-9C8B-AE103E4FC45C

P2860

Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab

Item

http://www.wikidata.org/entity/Q36714237

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab

@ast

Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab

@en

type

Item

label

Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab

@ast

Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab

@en

prefLabel

Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab

@ast

Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab

@en

P1476

Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab

@en

P2093

Chad J Hruska

http://www.w3.org/2001/XMLSchema#string

Patrick H Burkhart

http://www.w3.org/2001/XMLSchema#string

Robert J Bertoli

http://www.w3.org/2001/XMLSchema#string

Yorke D Young

http://www.w3.org/2001/XMLSchema#string

P2860

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses

Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.

WHO-EORTC classification for cutaneous lymphomas.

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Lymphomatoid papulosis in a patient treated with adalimumab for juvenile rheumatoid arthritis.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.

Adult T-cell leukemia/lymphoma triggered by adalimumab.

EBV-associated plasmablastic lymphoma in a patient with Crohn's disease after adalimumab treatment.

P304

56-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1016/J.JDCR.2014.12.006

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paul B Googe

P577

2015-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272379384

http://www.w3.org/2001/XMLSchema#string

P698

27051683

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab

P932

4802551

http://www.w3.org/2001/XMLSchema#string

Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab

about

P2860

P2860

Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932